Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. This maintained rating reinforced the bullish outlook that the analyst previously gave on Beam Therapeutics Inc. (NASDAQ:BEAM) in a January 21 note. Corwin noted that the existing clinical data on the lead program of Beam Therapeutics Inc. (NASDAQ:BEAM), the BEAM-302 treatment for alpha-1 antitrypsin deficiency, is an important foundation that supports continued confidence in the program’s trajectory.

The analyst also urged investors to watch the early 2026 clinical data update for BEAM-302, which he sees as a key catalyst for the stock. He highlights the alignment between Beam Therapeutics Inc. (NASDAQ:BEAM) and the FDA on a potential accelerated approval pathway based on 12-month biomarker data as an important de-risking step, offering a clearer and possibly faster regulatory route. Combined with strengthening clinical evidence and clearly defined upcoming milestones, this supportive regulatory backdrop reinforces his positive stance on the company and underpins his Buy rating.

Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops an integrated platform for precision genetic medicines.

While we acknowledge the risk and potential of BEAM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BEAM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Best High-Upside Materials Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.